Atomi Financial Group Inc. Boosts Stake in Novo Nordisk A/S (NYSE:NVO)

Atomi Financial Group Inc. increased its position in Novo Nordisk A/S (NYSE:NVO) by 4.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 32,146 shares of the company’s stock after purchasing an additional 1,473 shares during the quarter. Atomi Financial Group Inc.’s holdings in Novo Nordisk A/S were worth $2,765,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. Raymond James & Associates lifted its position in Novo Nordisk A/S by 1.0% during the third quarter. Raymond James & Associates now owns 3,526,821 shares of the company’s stock valued at $419,939,000 after buying an additional 36,223 shares during the period. Natixis Advisors LLC lifted its position in Novo Nordisk A/S by 2.7% during the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after acquiring an additional 80,070 shares during the period. International Assets Investment Management LLC boosted its stake in Novo Nordisk A/S by 10,608.4% during the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after acquiring an additional 1,796,635 shares in the last quarter. DSM Capital Partners LLC grew its holdings in Novo Nordisk A/S by 257,816.0% in the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock worth $227,516,000 after purchasing an additional 1,593,303 shares during the period. Finally, LPL Financial LLC increased its stake in shares of Novo Nordisk A/S by 3.6% during the third quarter. LPL Financial LLC now owns 1,362,782 shares of the company’s stock valued at $162,266,000 after purchasing an additional 47,496 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Price Performance

NYSE NVO opened at $78.74 on Tuesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The company has a market capitalization of $353.33 billion, a price-to-earnings ratio of 25.48, a PEG ratio of 0.84 and a beta of 0.45. The stock has a 50-day moving average of $97.15 and a 200 day moving average of $116.47. Novo Nordisk A/S has a one year low of $78.17 and a one year high of $148.15.

Wall Street Analyst Weigh In

Several analysts recently weighed in on NVO shares. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Finally, Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.